Immunome
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United S...
Latest News
6 days ago · benzinga.com
Immunome Analysts Cut Their Forecasts After Q3 ResultsImmunome Inc (NASDAQ:IMNM) on Monday posted a wider-than-expected loss for the third quarter.
10 days ago · businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class cancer therapies, announced today that on November 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 206,700 shares of common stock and 103,350 restricted stock units (“RSU.
13 days ago · zacks.com
Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should KnowThe consensus price target hints at a 74% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
13 days ago · zacks.com
4 Biotech Stocks Likely to Outpace Q3 Earnings EstimatesFour biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.
15 days ago · businesswire.com
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation ConferenceBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that its management will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 9 a.m. EST. Interested parties can access the live audio webcast of the presentation from the Investor Relations section of the company's website at www.immunome.com. The w.
18 days ago · businesswire.com
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid TumorsBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. Validation confirms that the application is complete,.
22 days ago · businesswire.com
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the presentation of additional clinical data for varegacestat, its investigational, oral, once-daily gamma secretase inhibitor, at the 2026 European Society for Medical Oncology (ESMO) Congress. The data were featured in four presentations, including a rapid oral presentation on patient-repo.
2 months ago · businesswire.com
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid TumorsBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for the treatment of advanced solid tumors.IM-1340 is designed to target a transport receptor with a unique tumor e.
3 months ago · businesswire.com
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C. Wainwright's 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.Interested parties can access the live audio webcast of the presentation from the Investor Relations section of the company's website at www.immunome.com.
3 months ago · marketbeat.com
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filingargenx NASDAQ: ARGX reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove IMNM